Atai Life Sciences N.V.
ATAI
$1.46
-$0.07-4.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -127.78% | -54.02% | 58.72% | -- | -52.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -127.78% | -54.02% | 58.72% | -- | -52.63% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -127.78% | -54.02% | 58.72% | -- | -52.63% |
| SG&A Expenses | -42.27% | -24.69% | -19.09% | -12.85% | 26.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.62% | -15.89% | -18.83% | -26.18% | -10.70% |
| Operating Income | 12.56% | 15.77% | 19.25% | 26.08% | 10.66% |
| Income Before Tax | -87.67% | -160.74% | -70.76% | 19.31% | 47.94% |
| Income Tax Expenses | 64.40% | -174.79% | -89.73% | -226.67% | -133.61% |
| Earnings from Continuing Operations | -103.69% | -160.66% | -69.88% | 20.31% | 58.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -96.12% | -97.14% | -92.18% | -45.45% | -48.11% |
| Net Income | -112.98% | -159.41% | -73.45% | 19.38% | 59.36% |
| EBIT | 12.56% | 15.77% | 19.25% | 26.08% | 10.66% |
| EBITDA | 12.97% | 15.85% | 19.31% | 26.20% | 10.80% |
| EPS Basic | -110.42% | -157.64% | -68.46% | 20.97% | 59.38% |
| Normalized Basic EPS | 9.05% | -8.79% | -71.48% | 16.82% | 17.39% |
| EPS Diluted | -109.15% | -165.48% | -68.46% | 20.97% | 59.69% |
| Normalized Diluted EPS | 9.05% | -24.01% | -71.48% | 16.82% | 17.39% |
| Average Basic Shares Outstanding | 1.18% | 3.10% | 2.95% | 1.99% | 0.09% |
| Average Diluted Shares Outstanding | 1.18% | -9.54% | 2.95% | 1.99% | 0.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |